Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms for Cardiac Allograft Dysfunction in Heart-Transplant Patients
NCT03102125Phase 4Recruiting
- Start
- Oct 2019
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of regadenoson in cardiac transplant rejection (HTR) (4 arms). Primary endpoint: Myocardial Perfusion Reserve at 60 months. Started Oct 2019; status: recruiting.
02
Drugs
regadenoson
03
Conditions
cardiac transplant rejection (HTR)
Beyond the preview
Go deeper on NCT03102125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03102125.